These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1252 related items for PubMed ID: 15123412

  • 1. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS.
    Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
    [Abstract] [Full Text] [Related]

  • 2. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
    Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR.
    Cancer; 2004 Mar 01; 100(5):892-9. PubMed ID: 14983482
    [Abstract] [Full Text] [Related]

  • 3. Bone health in men receiving androgen deprivation therapy for prostate cancer.
    Eastham JA.
    J Urol; 2007 Jan 01; 177(1):17-24. PubMed ID: 17161994
    [Abstract] [Full Text] [Related]

  • 4. Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates.
    Saad F, Abrahamsson PA, Miller K.
    BJU Int; 2009 Dec 01; 104(11):1573-9. PubMed ID: 20053188
    [Abstract] [Full Text] [Related]

  • 5. Bone loss in prostate cancer: evaluation, treatment and prevention.
    Saad F.
    Can J Urol; 2005 Feb 01; 12 Suppl 1():71-6; discussion 99-100. PubMed ID: 15780171
    [Abstract] [Full Text] [Related]

  • 6. New generation of bisphosphonates: broad clinical utility in breast and prostate cancer.
    Rosen LS.
    Oncology (Williston Park); 2004 May 01; 18(5 Suppl 3):26-32. PubMed ID: 15202585
    [Abstract] [Full Text] [Related]

  • 7. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.
    Smith MR.
    Oncology (Williston Park); 2004 May 01; 18(5 Suppl 3):21-5. PubMed ID: 15202584
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Bone health in men with prostate cancer: diagnostic and therapeutic considerations.
    Saad F, Perrotte P, Bénard F, McCormack M, Karakiewicz PI.
    Can J Urol; 2005 Jun 01; 12 Suppl 2():9-15. PubMed ID: 16018826
    [Abstract] [Full Text] [Related]

  • 10. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?
    Higano CS.
    Nat Clin Pract Urol; 2008 Jan 01; 5(1):24-34. PubMed ID: 18185511
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA, Sarna L, Oka RK, Vredevoe DL, Rettig MB, Aronson WJ.
    Urology; 2004 Aug 01; 64(2):335-40. PubMed ID: 15302490
    [Abstract] [Full Text] [Related]

  • 15. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.
    Israeli RS, Ryan CW, Jung LL.
    J Urol; 2008 Feb 01; 179(2):414-23. PubMed ID: 18076933
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Preservation of bone health in prostate cancer.
    Lattouf JB, Saad F.
    Curr Opin Support Palliat Care; 2007 Oct 01; 1(3):192-7. PubMed ID: 18685362
    [Abstract] [Full Text] [Related]

  • 18. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Wilcox A, Carnes ML, Moon TD, Tobias R, Baade H, Stamos E, Elliott ME.
    Ann Pharmacother; 2006 Dec 01; 40(12):2107-14. PubMed ID: 17132807
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 63.